Date: Jan 01, 2014 Source: Cambridge Healthtech Institute (
click here to go to the source)
Ssheduled session at 11th Annual Strategic Alliance Managment Congress May 5-7, 2014. Organzied by Cambridge Healthtech Institute
Discusants:
* Mark Coflin, Executive Director, Business Development and Licensing, Alliance Management, Novartis Pharmaceuticals Corporation
* David Tollerud, Ph.D., COO, Regenerex
Novartis and Regenerex have recently formed a research alliance to advance novel cell therapy to treat conditions with high unmet need. This presentation will discuss a strategic state investment that brought a translational research institute including 23 families to form the foundation for rapid expansion of federally funded research at the University of Louisville. A Biotech start-up company, Regenerex LLC was formed to promote R&D activities and ultimately commercialization of the platform technology funded largely by federal (NIH) and state small business grants. Regenerex and the University formed a highly successful public/private partnership that supported several successful clinical trials and carried the flagship tolerance trial to FDA late Phase II. These clinical trial results formed the basis for a strategic global partnership between Regenerex and Novartis that includes basic and translational research initiatives as well as clinical trials to deliver an innovative portfolio of novel cell therapy therapeutics to treat patients in need.
